#Cepheid #Democratic Republic of the Congo #Ebola #Bundibugyo

Cepheid's Commitment to Fighting Ebola in Africa

Introduction

In a determined effort to tackle the ongoing outbreak of Ebola Bundibugyo virus (BDBV) in the Democratic Republic of the Congo (DRC) and Uganda, Cepheid, a subsidiary of Danaher Corporation, has made a significant donation of its Xpert® Hemorrhagic Fever panel tests. This initiative comes in the wake of the World Health Organization's (WHO) declaration of a Public Health Emergency on May 17, 2026. The need for improved diagnostic capabilities has never been more urgent as the region battles this deadly disease.

A Timely Response

The initial shipment of Xpert® Hemorrhagic Fever tests has already reached the DRC, and Cepheid is collaborating closely with various global health organizations, including the U.S. government and WHO, to ensure additional production and speedy deployment. Dr. Connie Savor, Cepheid's Chief Medical Officer, emphasized the importance of rapid testing, stating, "Cepheid is working urgently with global health partners to deploy the Xpert Hemorrhagic Fever panel test in affected regions, particularly in regions at high risk of cross-border transmission."

The panel tests are designed to detect viruses responsible for hemorrhagic fevers, such as the Ebola virus, Crimean Congo hemorrhagic fever, Marburg virus, and Lassa virus, providing results within one hour. This immediacy is critical in outbreak situations where timely diagnosis can greatly impact treatment and containment.

Infrastructure for Rapid Testing

Cepheid’s GeneXpert® systems, which are already installed across several African nations, including DRC, Uganda, South Sudan, and Rwanda, offer the necessary infrastructure to support efficient testing in decentralized locations. This capability proves invaluable during health emergencies, as it facilitates quick isolation, effective treatment, and detailed outbreak control.

Larry Kelmar, Cepheid's Vice President of Government Programs and Pharmaceutical Collaborations, highlighted the essential role of public-private partnerships in the response to such crises, stating, "The response is only possible through coordinated public-private partnerships."

With over two decades of experience addressing infectious disease emergencies, Cepheid's commitment to enhancing public health responses is evident. The company has a successful history of deploying rapid molecular tests during previous Ebola outbreaks, which have demonstrated their effectiveness in reducing the time between symptom onset and laboratory confirmation.

History of Involvement in Health Crises

Cepheid’s expertise in infectious disease diagnostics emerged prominently during the 2014-2016 West Africa Ebola outbreak when the Xpert® Ebola test received Emergency Use Authorization from the FDA, allowing it to be deployed expeditiously to control the epidemic. Subsequently, in early 2020, they were the first to receive FDA Emergency Use Authorization for a point-of-care molecular PCR test for COVID-19, underscoring their swift adaptation to public health needs.

With the recent emergence of Mpox, Cepheid continues to innovate. By February 2023, it received its first EUA for a point-of-care molecular test for Mpox, which was authorized for use even under resource-limited conditions worldwide.

Conclusion

Cepheid’s initiative to deploy the Xpert® Hemorrhagic Fever panel tests highlights its ongoing dedication to global health advancement. As the DRC and Uganda face significant challenges from the BDBV outbreak, Cepheid's swift action, extensive experience, and pre-existing infrastructure position it as a vital player in the global health landscape. The collaboration with organizations like WHO and government agencies ensures that the necessary tools for diagnosis and treatment are available to save lives and control outbreaks effectively.

For more information about Cepheid and their continuous endeavors to improve healthcare through innovative diagnostics, visit www.cepheid.com.